Latest Breaking News On - News ratings for eyepoint pharmaceuticals daily - Page 1 : comparemela.com

Monashee Investment Management LLC Takes $4 04 Million Position in EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT)

Monashee Investment Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 175,000 shares of the company’s stock, valued at approximately $4,044,000. EyePoint Pharmaceuticals accounts for about 0.7% of Monashee […]

Robertw bairdDavidr guyerSecurities exchange commissionQuarter for eyepoint pharmaceuticalsInvestment advisersDeutsche bankEyepoint pharmaceuticals company profileChina universal asset management coEyepoint pharmaceuticalsEyepoint pharmaceuticals incMirae asset global investments coNews ratings for eyepoint pharmaceuticals dailyMonashee investment managementEyepoint pharmaceuticals stock performanceToth financial advisory corpInsider activity at eyepoint pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $11 16

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $11.16, but opened at $10.90. EyePoint Pharmaceuticals shares last traded at $11.13, with a volume of 79,034 shares. Analyst Ratings Changes Several research analysts have recently issued reports on the company. […]

Davidr guyerRobertw bairdInstitutional trading of eyepoint pharmaceuticalsSecurities exchange commissionEyepoint pharmaceuticals incEyepoint pharmaceuticals company profileMirae asset global investments coEyepoint pharmaceuticals stockNews ratings for eyepoint pharmaceuticals dailyDeutsche bankInvestment advisersEyepoint pharmaceuticalsTower research capitalAmeritas investment partners incGet free reportPoint pharmaceuticals

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Receives Consensus Recommendation of Buy from Analysts

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Receives Consensus Recommendation of Buy from Analysts
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdYork mellon corpEyepoint pharmaceuticals company profileSecurities exchange commissionEyepoint pharmaceuticals stockJpmorgan chase coAnalyst recommendations for eyepoint pharmaceuticalsInsider activity at eyepoint pharmaceuticalsEyepoint pharmaceuticals incEyepoint pharmaceuticalsHedge funds weigh in on eyepoint pharmaceuticalsMirae asset global investments coNews ratings for eyepoint pharmaceuticals dailyJump financialTd asset management incGet free report

Analysts Set EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Target Price at $34 00

Analysts Set EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Target Price at $34 00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Securities exchange commissionHermes incInsider activity at eyepoint pharmaceuticalsEyepoint pharmaceuticals incFranklin resources incAnalyst recommendations for eyepoint pharmaceuticalsEyepoint pharmaceuticals price performanceNews ratings for eyepoint pharmaceuticals dailyJennison associatesJpmorgan chase coEyepoint pharmaceuticals company profileVanguard group incInstitutional investors weigh in on eyepoint pharmaceuticalsEyepoint pharmaceuticalsGet free reportOne financial

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Given Consensus Recommendation of Buy by Analysts

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Given Consensus Recommendation of Buy by Analysts
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdChina universal asset management coEyepoint pharmaceuticalsNews ratings for eyepoint pharmaceuticals dailyJpmorgan chase coEyepoint pharmaceuticals incTower research capitalAnalyst recommendations for eyepoint pharmaceuticalsSherbrooke park advisersInvestment advisersEyepoint pharmaceuticals price performanceToth financial advisory corpGet free reportOne financialCormorant asset managementUniversal asset management